Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of ITI-214 in Patients With Heart Failure
| Status: | Recruiting |
|---|---|
| Conditions: | Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 7/28/2018 |
| Start Date: | July 10, 2018 |
| End Date: | December 2019 |
| Contact: | Kimberly Vanover, PhD |
| Email: | itciclinicaltrials@intracellulartherapies.com |
| Phone: | 646-440-9333 |
Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of Escalating Single Doses of ITI-214 in Patients With Systolic Heart Failure
This is a Phase I/II randomized, double-blind, placebo-controlled, single rising dose study
in patients with systolic heart failure to evaluate the safety and tolerability of ITI-214.
in patients with systolic heart failure to evaluate the safety and tolerability of ITI-214.
Inclusion Criteria:
- NYHA class II-III heart failure
- Ejection fraction equal to or below 35%
- On stable heart failure drug treatment
Exclusion Criteria:
- Considered medically inappropriate for study participation
We found this trial at
2
sites
Click here to add this to my saved trials
3400 N Charles St
Baltimore, Maryland 21205
Baltimore, Maryland 21205
410-516-8000
Principal Investigator: Nisha Gilotra, MD
Johns Hopkins University The Johns Hopkins University opened in 1876, with the inauguration of its...
Click here to add this to my saved trials